Discovery to Cure News
Advance of the Year: Progress in Treating Rare Cancers This year, ASCO names Progress in Treating Rare Cancers as the Advance of the Year. In the United States, rare cancers account for approximately 20% of all cancers diagnosed each year, and incidence rates vary worldwide. Progress has historically lagged behind the achievements made in more common cancers; however, five major studies this past year offer significant steps forward, making this a notable year for advances in rare cancers. Research from the Yale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences was selected as #4: Trastuzumab effective for a rare form of endometrial cancer.
- December 17, 2018
Dr. Sandra Carson appointed as new Division Director for Reproductive Endocrinology and Infertility in the Department of OBGYN
It is with great pride that we announce the appointment of Dr. Sandra Carson as Director of the Division of Reproductive Endocrinology and Infertility.
- August 08, 2016
The 2016 Yale Discovery to Cure Kick-Off Event was on Saturday, August 6, 2016 at the Connecticut Beardsley Zoo, Bridgeport, CT.
- May 25, 2016
New inroads are being made all of the time concerning women’s reproductive cancers. Discovery to cure at Yale was launched in 2003 to better provide women with new methods of prevention, early detection, and treatment. Dr. Elena Ratner from the Yale School of Medicine and Uterine Cancer Survivor, Ruth-Ann Ornstein, who is doing well and working hard to grow “Discovery to Cure” so that women can be better cared for.
- April 08, 2016
AACR Molecular Cancer Therapeutics: TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Chemoresistance is a major hurdle in the management of patients with epithelial ovarian cancer and is responsible for its high mortality. Studies have shown that chemoresistance is due to the presence of a subgroup of cancer cells with stemness properties and a high capacity for tumor repair. We have developed a library of super-benzopyran analogues to generate potent compounds that can induce cell death in chemoresistant cancer stem cells.
- March 10, 2016
British Journal of Cancer: Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair
Platinum resistance may be attributable to inherent or acquired proficiency in homologous recombination repair (HRR) in epithelial ovarian cancer (EOC). The objective of this study was to evaluate the efficacy of the small molecule inhibitor triapine to disrupt HRR and sensitise BRCA wild-type EOC cells to platinum-based combination therapy in vitro and in vivo.
- September 22, 2015
NEW HAVEN >> Beverly Levy knew that ovarian cancer was a challenge to diagnose and treat, so she started a walk in 2013 to bring awareness and raise money for research.
- July 23, 2015
Five researchers from the Yale School of Medicine have received grants from Discovery to Cure, a program at the Department of Obstetrics, Gynecology, and Reproductive Sciences that advances the prevention, early detection, and treatment of women’s reproductive cancers such as ovarian, uterine, cervical, vaginal, and vulvar cancers.
- June 06, 2014
Lauralton Hall student Ann Marie Guzzi discusses her experience in the Discovery to Cure High School Internship
- November 19, 2013
A new joint venture, CanTx, Inc., has a simple mission: cure ovarian cancer. The venture—announced on Nov. 6—brings together the research advances of Gil Mor, Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University, the first researcher to isolate and clone ovarian cancer stem cells, with Novogen, an Australian-US biotech company that has developed compounds that target these cancer cells.